Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 454

1.

The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer.

Barney BM, Petersen IA, Mariani A, Dowdy SC, Bakkum-Gamez JN, Haddock MG.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):109-15. doi: 10.1016/j.ijrobp.2012.03.011. Epub 2012 Apr 28.

PMID:
22543202
2.

Vaginal brachytherapy for early stage uterine papillary serous and clear cell endometrial cancer.

Townamchai K, Berkowitz R, Bhagwat M, Damato AL, Friesen S, Lee LJ, Matulonis U, O'Farrell D, Viswanathan AN.

Gynecol Oncol. 2013 Apr;129(1):18-21. doi: 10.1016/j.ygyno.2012.12.026. Epub 2012 Dec 21.

PMID:
23262378
3.

Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy.

Murphy KT, Rotmensch J, Yamada SD, Mundt AJ.

Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1272-6. Review.

PMID:
12654437
4.

Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy.

Turner BC, Knisely JP, Kacinski BM, Haffty BG, Gumbs AA, Roberts KB, Frank AH, Peschel RE, Rutherford TJ, Edraki B, Kohorn EI, Chambers SK, Schwartz PE, Wilson LD.

Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):77-84.

PMID:
9422561
5.

Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma.

Mundt AJ, Murphy KT, Rotmensch J, Waggoner SE, Yamada SD, Connell PP.

Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1154-60.

PMID:
11483324
6.

Vaginal brachytherapy alone is sufficient adjuvant treatment of surgical stage I endometrial cancer.

Solhjem MC, Petersen IA, Haddock MG.

Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1379-84. Review.

PMID:
16029796
7.

Ten-year outcome including patterns of failure and toxicity for adjuvant whole abdominopelvic irradiation in high-risk and poor histologic feature patients with endometrial carcinoma.

Stewart KD, Martinez AA, Weiner S, Podratz K, Stromberg JS, Schray M, Mitchell C, Sherman A, Chen P, Brabbins DA.

Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):527-35.

PMID:
12243832
8.

Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy.

Mehta N, Yamada SD, Rotmensch J, Mundt AJ.

Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):1004-9.

PMID:
14575831
9.

Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging?

Kwon JS, Abrams J, Sugimoto A, Carey MS.

Int J Gynecol Cancer. 2008 Jul-Aug;18(4):820-4. Epub 2007 Sep 24.

PMID:
17892450
10.

Improved outcome at 10 years for serous-papillary/clear cell or high-risk endometrial cancer patients treated by adjuvant high-dose whole abdomino-pelvic irradiation.

Martinez AA, Weiner S, Podratz K, Armin AR, Stromberg JS, Stanhope R, Sherman A, Schray M, Brabbins DA.

Gynecol Oncol. 2003 Sep;90(3):537-46.

PMID:
13678721
11.

Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy.

Mundt AJ, McBride R, Rotmensch J, Waggoner SE, Yamada SD, Connell PP.

Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1145-53.

PMID:
11483323
12.

Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer.

Kiess AP, Damast S, Makker V, Kollmeier MA, Gardner GJ, Aghajanian C, Abu-Rustum NR, Barakat RR, Alektiar KM.

Gynecol Oncol. 2012 Nov;127(2):321-5. doi: 10.1016/j.ygyno.2012.07.112. Epub 2012 Jul 28.

PMID:
22850412
13.

Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study.

Sutton G, Axelrod JH, Bundy BN, Roy T, Homesley HD, Malfetano JH, Mychalczak BR, King ME.

Gynecol Oncol. 2005 Jun;97(3):755-63.

PMID:
15913742
14.

Predictive factors of recurrence following adjuvant vaginal cuff brachytherapy alone for stage I endometrial cancer.

Dunn EF, Geye H, Platta CS, Gondi V, Rose S, Bradley KA, Anderson BM.

Gynecol Oncol. 2014 Jun;133(3):494-8. doi: 10.1016/j.ygyno.2014.03.554. Epub 2014 Mar 20.

PMID:
24657301
15.

Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma.

Horowitz NS, Peters WA 3rd, Smith MR, Drescher CW, Atwood M, Mate TP.

Obstet Gynecol. 2002 Feb;99(2):235-40.

PMID:
11814503
16.

High-dose rate brachytherapy for Stage I/II papillary serous or clear cell endometrial cancer.

DuBeshter B, Estler K, Altobelli K, McDonald S, Glantz C, Angel C.

Gynecol Oncol. 2004 Aug;94(2):383-6.

PMID:
15297176
17.

Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma.

Sood BM, Jones J, Gupta S, Khabele D, Guha C, Runowicz C, Goldberg G, Fields A, Anderson P, Vikram B.

Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):208-16.

PMID:
12909235
18.

The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.

Cirisano FD Jr, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS, Soper JT, Clarke-Pearson DL.

Gynecol Oncol. 2000 Apr;77(1):55-65.

PMID:
10739691
19.

Pathologic stage I-II endometrial carcinoma in the elderly: radiotherapy indications and outcome.

Citron JR, Sutton H, Yamada SD, Mehta N, Mundt AJ.

Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1432-8.

PMID:
15275729
20.

Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium.

Creasman WT, Kohler MF, Odicino F, Maisonneuve P, Boyle P.

Gynecol Oncol. 2004 Dec;95(3):593-6.

PMID:
15581969

Supplemental Content

Support Center